Biotech firm ImmunoScape on Tuesday announced USD11m under global equity financing round led by US-based venture firm Anzu Partners and joined by University of Tokyo Edge Capital (UTEC) in Japan and NPR Holdings in Indonesia.
ImmunoScape's immune profiling platform, which provides deep insights into the T-cells of the human immune system, is already intensely engaged in COVID-19 related programmes in three continents. The company has established collaborations with several vaccine development companies, including the San Diego-based Arcturus, which is running clinical trials in Singapore.
In global collaborations with Massachusetts General Hospital, University of Parma (Italy) and Duke-NUS, ImmunoScape is evaluating COVID-19 patients and recovered individuals. It is building a large data set on human T-cell response to COVID-19 to develop new therapies and better vaccines with its partners. ImmunoScape's technology is based on work from Stanford University and A*STAR of Singapore, disclosed ImmunoScape's co-founder and COO Dr Alessandra Nardin.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne